InvestorsHub Logo
Followers 20
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Friday, 05/28/2021 12:46:52 PM

Friday, May 28, 2021 12:46:52 PM

Post# of 238
Aptevo Therapeutics price target lowered to $50 from $64 at Roth Capital
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Aptevo Therapeutics to $50 from $64 and keeps a Buy rating on the shares. Aschoff views the potential Tang Capital takeout at $50/share as highly likely, and therefore a more relevant investment catalyst, the analyst tells investors in a research note.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APVO News